仁度生物(688193) - 2022 Q1 - 季度财报

Financial Performance - The company's revenue for Q1 2022 was ¥93,280,166.18, representing a year-over-year increase of 7.43%[3] - The net profit attributable to shareholders decreased by 13.54% to ¥16,806,634.77[3] - The basic earnings per share for the period was ¥0.56, down 13.54% from the previous year[3] - The weighted average return on equity decreased by 2.95 percentage points to 5.66%[3] - Net profit for Q1 2022 was ¥16,806,634.77, down from ¥19,437,639.40 in Q1 2021, a decrease of about 13.4%[18] - The total comprehensive income for Q1 2022 was ¥16,784,019.05, compared to ¥19,480,470.18 in Q1 2021, a decrease of about 13.9%[18] Cash Flow and Assets - The net cash flow from operating activities increased significantly by 192.07% to ¥5,961,279.66[3] - The company's cash and cash equivalents as of March 31, 2022, amounted to RMB 874,755,465.48, significantly up from RMB 197,942,433.34 at the end of 2021, representing a growth of 341.5%[13] - Cash flow from operating activities generated a net amount of ¥5,961,279.66 in Q1 2022, up from ¥2,041,065.05 in Q1 2021, indicating a significant improvement[21] - Cash and cash equivalents at the end of Q1 2022 totaled ¥875,430,465.48, compared to ¥167,029,781.05 at the end of Q1 2021, reflecting a substantial increase[22] - Investment activities resulted in a net cash outflow of ¥3,466,731.24 in Q1 2022, an improvement from a net outflow of ¥5,099,308.39 in Q1 2021[22] Assets and Liabilities - Total assets at the end of the reporting period reached ¥1,083,745,413.96, an increase of 186.24% compared to the end of the previous year[4] - The total liabilities as of March 31, 2022, were RMB 124,399,111.98, up from RMB 90,860,601.43, indicating a growth of 37%[15] - Total current assets reached RMB 982,345,585.28, compared to RMB 282,537,896.95 at the end of 2021, marking an increase of 248.5%[13] - The total equity attributable to shareholders increased by 233.40% to ¥959,346,301.98[4] - The total equity attributable to shareholders increased to RMB 959,346,301.98 from RMB 287,747,428.24, a rise of 233.5%[15] Research and Development - Research and development expenses amounted to ¥7,267,729.68, accounting for 7.79% of revenue, an increase of 0.14 percentage points[4] - Research and development expenses rose to ¥7,267,729.68 in Q1 2022, compared to ¥6,643,350.37 in Q1 2021, an increase of approximately 9.4%[17] - The company is focusing on expanding its market presence and enhancing its product offerings through ongoing research and development initiatives[16] Strategic Outlook - The company reported non-recurring gains of ¥705,846.34 after tax[7] - The company reported a net profit margin improvement, with net profit for Q1 2022 expected to reflect positive growth trends[16] - The company has plans for strategic partnerships and potential acquisitions to bolster its market position and drive future growth[16] - The management provided optimistic guidance for the upcoming quarters, anticipating continued revenue growth and improved operational efficiency[16] Operating Costs - Total operating costs increased to ¥73,195,654.95 in Q1 2022 from ¥62,782,489.99 in Q1 2021, representing an increase of approximately 17.5%[17] - Total operating revenue for Q1 2022 was RMB 93,280,166.18, an increase of 7.8% compared to RMB 86,825,799.85 in Q1 2021[16] - Total revenue from sales of goods and services received cash of ¥74,344,188.17 in Q1 2022, down from ¥85,652,644.15 in Q1 2021, a decline of about 13.5%[21] Shareholder Information - The total number of common shareholders at the end of the reporting period was 9,049[9] - The company recorded investment income of ¥735,301.12 in Q1 2022, significantly higher than ¥114,622.64 in Q1 2021, marking an increase of approximately 540.5%[17]